{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer%2C+Small+Cell+Lung+Cancer&page=74",
    "query": {
      "condition": "Non-Small Cell Lung Cancer, Small Cell Lung Cancer",
      "page": 74
    },
    "page_size": 10
  },
  "pagination": {
    "page": 74,
    "page_size": 10,
    "total_count": 3681,
    "total_pages": 369,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer%2C+Small+Cell+Lung+Cancer&page=75&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer%2C+Small+Cell+Lung+Cancer&page=73&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T17:49:03.866Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00583830",
      "title": "A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Mapatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Human Genome Sciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2007-01",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2013-08-08",
      "last_synced_at": "2026-11-03T17:49:03.866Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Rancho Mirage, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00583830"
    },
    {
      "nct_id": "NCT06279728",
      "title": "Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "EGFRm Advanced Non-Small Cell Lung Cancer",
        "EGFRm Metastatic Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Datopotamab deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2025-07-03",
      "last_synced_at": "2026-11-03T17:49:03.866Z",
      "location_count": 14,
      "location_summary": "Springdale, Arkansas • Honolulu, Hawaii • Bowling Green, Kentucky + 10 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Bowling Green",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06279728"
    },
    {
      "nct_id": "NCT00549328",
      "title": "Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer, Non-Small Cell"
      ],
      "interventions": [
        {
          "name": "Pazopanib (GW786034)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2008-02",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2014-11-19",
      "last_synced_at": "2026-11-03T17:49:03.866Z",
      "location_count": 13,
      "location_summary": "Scottsdale, Arizona • Fort Myers, Florida • Orlando, Florida + 10 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Duluth",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00549328"
    },
    {
      "nct_id": "NCT05274451",
      "title": "A Study to Investigate LYL797 in Adults With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "TNBC - Triple-Negative Breast Cancer",
        "Non-small Cell Lung Cancer",
        "Non Small Cell Lung Cancer",
        "Non Small Cell Lung Cancer Metastatic",
        "Non-Small Cell Carcinoma of Lung, TNM Stage 4",
        "Advanced Breast Cancer",
        "Advanced Lung Carcinoma",
        "NSCLC",
        "NSCLC, Recurrent",
        "NSCLC Stage IV",
        "Relapsed Cancer",
        "Relapse/Recurrence",
        "Recurrent Breast Cancer",
        "Recurrent NSCLC",
        "Platinum-resistant Ovarian Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer",
        "Endometrial Cancer",
        "Endometrioid Tumor",
        "High Grade Serous Carcinoma",
        "Ovarian Epithelial Cancer"
      ],
      "interventions": [
        {
          "name": "LYL797",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Lyell Immunopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2022-03-29",
      "completion_date": "2024-11-27",
      "has_results": false,
      "last_update_posted_date": "2025-07-01",
      "last_synced_at": "2026-11-03T17:49:03.866Z",
      "location_count": 18,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05274451"
    },
    {
      "nct_id": "NCT02298153",
      "title": "A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NSCLC (Non-small Cell Lung Carcinoma)",
        "UC (Urothelial Cancer)"
      ],
      "interventions": [
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2015-01-27",
      "completion_date": "2017-11-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-11-03T17:49:03.866Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02298153"
    },
    {
      "nct_id": "NCT00081107",
      "title": "Epothilone D in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Platinum-Based Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "epothilone D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-12",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2013-06-05",
      "last_synced_at": "2026-11-03T17:49:03.866Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00081107"
    },
    {
      "nct_id": "NCT06051695",
      "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Colorectal Cancer",
        "NSCLC",
        "Non Small Cell Lung Cancer",
        "NSCLC, Recurrent",
        "Non-Small Cell Squamous Lung Cancer",
        "Pancreas Cancer",
        "Pancreatic Neoplasm",
        "Colorectal Adenocarcinoma",
        "CRC",
        "Colon Cancer",
        "Rectal Cancer",
        "Cancer",
        "Ovarian Cancer",
        "Ovarian Neoplasms",
        "Mesothelioma",
        "Mesothelioma, Malignant",
        "Ovary Cancer",
        "Lung Cancer",
        "MESOM"
      ],
      "interventions": [
        {
          "name": "A2B694",
          "type": "BIOLOGICAL"
        },
        {
          "name": "A2B543",
          "type": "BIOLOGICAL"
        },
        {
          "name": "xT CDx with HLA-LOH Assay",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "A2 Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 474,
      "start_date": "2024-04-03",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-11-03T17:49:03.866Z",
      "location_count": 12,
      "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06051695"
    },
    {
      "nct_id": "NCT01234038",
      "title": "Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ISIS EIF4E Rx",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2010-11",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2018-06-27",
      "last_synced_at": "2026-11-03T17:49:03.866Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Hot Springs, Arkansas + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01234038"
    },
    {
      "nct_id": "NCT07315113",
      "title": "Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "EGFR Mutation Positive Non-small Cell Lung Cancer",
        "EGFR Mutated Non-small Cell Lung Cancer Patients"
      ],
      "interventions": [
        {
          "name": "NXP900",
          "type": "DRUG"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nuvectis Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2025-12-18",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-11-03T17:49:03.866Z",
      "location_count": 6,
      "location_summary": "Calverton, Maryland • Boston, Massachusetts • Eugene, Oregon + 3 more",
      "locations": [
        {
          "city": "Calverton",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07315113"
    },
    {
      "nct_id": "NCT07261631",
      "title": "Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Non-Small Cell Lung Cancer",
        "HR+/HER2- Ductal and Lobular Breast Cancer",
        "Triple Negative Breast Cancer",
        "Colorectal Cancer",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "68Ga-NNS309",
          "type": "DRUG"
        },
        {
          "name": "177Lu-DFC413",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2025-11-24",
      "completion_date": "2029-05-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-03T17:49:03.866Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07261631"
    }
  ]
}